Evotec Achieves Twelfth Boehringer Milestone

Evotec AG has achieved a twelfth milestone in its research alliance with Boehringer Ingelheim, triggering a $2.9 million payment to Evotec. The milestone was for the transition of an oncology program into lead optimization.

Dr. Mario Polywka, chief operating officer of Evotec said, “This is the twelfth milestone achieved as part of this alliance with Boehringer Ingelheim and the third against an oncology target. We are now in our eighth year of this collaboration and this milestone again validates the strength of the joint Evotec / Boehringer research groups as they drive new drug candidates to the clinic.”

The multi-target drug discovery alliance aims to jointly identify and develop preclinical development candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic, respiratory diseases, and cancer. Boehringer Ingelheim has full ownership and global responsibility for clinical development, manufacturing and commercialization of the compounds identified. In return, Evotec receives ongoing research payments and preclinical milestones.